Annales De Dermatologie Et De Venereologie最新文献

{"title":"Mammary and extramammary diffuse dermal angiomatosis: a case series and review of the literature.","authors":"C Decaestecker, E Diaz, E Crickx, J-D Bouaziz, C Vanhaecke, M-A Viguier, E Brenaut, D Kottler, P Courville, C Tamarit, M Battistella, C Bocciarelli, G Leflahec, C Emonet, P Carvalho, B Tedbirt","doi":"10.1016/j.annder.2025.103397","DOIUrl":"10.1016/j.annder.2025.103397","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 3","pages":"103397"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of hypertensive leg ulcers: A French national survey","authors":"Y. Zerdani ,&nbsp;H. Nguyen-Chi ,&nbsp;J.-B. Monfort ,&nbsp;P. Senet ,&nbsp;E. Tella ,&nbsp;E. Mahé ,&nbsp;The Groupe Angiodermatologie (GAD) of the Société Française de Dermatologie","doi":"10.1016/j.annder.2025.103353","DOIUrl":"10.1016/j.annder.2025.103353","url":null,"abstract":"<div><h3>Background</h3><div>Hypertensive leg ulcers (HLUs) are superficial, rapidly spreading, necrotic ulcers that are frequently resistant to standard local wound care. The available literature on HLU management is relatively poor. This survey-based study aimed to evaluate the management of HLUs in France.</div></div><div><h3>Methods</h3><div>A questionnaire was sent in December 2019 to all members of the Angiodermatology Group of the French Society of Dermatology. The questionnaire collected information about physicians and their department, and about their management of HLUs, including examinations and specific and non-specific topical and systemic treatments.</div></div><div><h3>Results</h3><div>Forty-four physicians responded. The most frequently performed examinations were lower-limb arterial Doppler (88.6%), ankle-brachial pressure index tests (83.7%) and venous Doppler (60.5%). Blood sampling for autoimmunity testing was requested by 27.3% of physicians and skin biopsy by 20.5%. The most frequently used first-line therapy was skin grafting (97.7%). Other treatments included topical steroids (58.1%), negative-pressure therapy (15.9%), electrostimulation (15.9%), auto-haemotherapy (14.0%), and iloprost (11.4%). The mechanism of action of electrostimulation is not very clear. Its main benefit lies in controlling the pain of HLU. Iloprost appears to be an interesting vasodilator although it has not been validated to date. An additional antiplatelet agent was proposed by 19.0% of the physicians and modification of anticoagulant treatment (use of a vitamin K antagonist in addition to direct oral anticoagulants) was proposed by 19.5% of physicians.</div></div><div><h3>Discussion</h3><div>The survey results showed that HLU evaluation involved searching for associated peripheral arterial disease and that HLU management in France was disparate. Skin grafting was the sole consensual treatment and was generally used as a first-line option. Other treatments require further evaluation. Management disparities could be reduced by the drafting and publication of a consensus guideline to harmonise HLU management.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103353"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apremilast: Real-life efficacy and safety in psoriasis limited to the nails","authors":"M. Iorizzo ,&nbsp;G. Damiani ,&nbsp;S.R. Lipner ,&nbsp;A. Pacifico ,&nbsp;D. Rigopoulos ,&nbsp;A. Sechi ,&nbsp;A. Villani ,&nbsp;I. Zaraa ,&nbsp;B. Richert","doi":"10.1016/j.annder.2025.103377","DOIUrl":"10.1016/j.annder.2025.103377","url":null,"abstract":"<div><h3>Background</h3><div>Apremilast, an oral phosphodiesterase inhibitor, offers advantages in psoriasis patients in whom biologics are not approved or accepted and where topical treatments have failed. Psoriasis involving the nails, scalp, and genitals is difficult to treat and is associated with a significant decrease in quality of life, requiring an effective treatment.</div></div><div><h3>Objectives</h3><div>This study aimed to retrospectively assess the efficacy and safety of apremilast 30 mg twice daily in treating psoriasis limited to the nails.</div></div><div><h3>Methods</h3><div>The charts of 55 adult patients with nail psoriasis treated with apremilast were retrospectively evaluated. Baseline characteristics, including the nail psoriasis severity index (NAPSI) and dermatology life quality index (DLQI), were recorded.</div></div><div><h3>Results</h3><div>At 6 months of treatment, a statistically significant decrease in both the NAPSI score (44.7 ± 26.9 vs. 19.03 ± 14.2) and the DLQI score (14.5 ± 5 vs. 7.2 ± 4.1) was observed (<em>p</em> &lt; 0.01). None of the patients discontinued the treatment due to side effects.</div></div><div><h3>Conclusions</h3><div>This study shows improvements in nail psoriasis severity and quality of life with apremilast treatment. Despite potential confounders like psoriatic arthritis, smoking, and manual work, consistent improvements were observed. Apremilast appears to be a valuable treatment option for nail psoriasis. However, further prospective studies are necessary to address the limitations of this retrospective analysis and explore additional endpoints.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103377"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143898928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bullous pemphigoid following radiotherapy combined with ipilimumab-nivolumab therapy","authors":"A. Pankakoski,&nbsp;J. Panelius,&nbsp;N. Kluger","doi":"10.1016/j.annder.2025.103367","DOIUrl":"10.1016/j.annder.2025.103367","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103367"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the French version of the hidradenitis suppurativa quality of life (HiSQOL) questionnaire","authors":"S. Berros ,&nbsp;A.-S. Ficheux ,&nbsp;L. Misery ,&nbsp;N. Jouan ,&nbsp;E. Brenaut","doi":"10.1016/j.annder.2025.103379","DOIUrl":"10.1016/j.annder.2025.103379","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103379"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143898994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of excess weight on clinical features of psoriasis and efficacy of biologic therapies in children with severe psoriasis: Analysis of data from the BiPe cohorts","authors":"E. Mahé ,&nbsp;V. di Lernia ,&nbsp;A.-C. Bursztejn ,&nbsp;S. Hadj-Rabia ,&nbsp;N. Quiles-Tsimaratos ,&nbsp;A. Belloni Fortina ,&nbsp;I. Neri ,&nbsp;A. Lasek ,&nbsp;A. Maruani ,&nbsp;G. Chaby ,&nbsp;J. Gottlieb ,&nbsp;S. Barbarot ,&nbsp;H. Aubert ,&nbsp;C. Droitcourt ,&nbsp;S. Mallet ,&nbsp;A. Phan ,&nbsp;M. Severino-Freire ,&nbsp;F. Boralévi ,&nbsp;H. Barthélémy ,&nbsp;C. Girard ,&nbsp;A. Beauchet","doi":"10.1016/j.annder.2025.103376","DOIUrl":"10.1016/j.annder.2025.103376","url":null,"abstract":"<div><h3>Background</h3><div>Being overweight or obese is associated with both the occurrence of childhood psoriasis and increased severity thereof. We evaluated the impact of being overweight or obese on the clinical features of severe psoriasis in children treated with etanercept, adalimumab, or ustekinumab, and on the therapeutic effectiveness of these treatments using data from the BiPe cohorts.</div></div><div><h3>Patients and methods</h3><div>Children from the BiPe cohorts with available baseline body mass index data were included. Data from two groups, “normal weight” and “overweight-to-obese” (OTO), and from two OTO subgroups, overweight and obese, were analyzed.</div></div><div><h3>Results</h3><div>Of the 134 children included, 98 (73.1%) were of normal weight, and 36 (26.9%) were OTO, including 21 (15.7%) overweight and 15 (11.2%) obese children. There were no between-group differences in age at psoriasis onset, family history, clinical features, or severity. Compared to the normal weight group, psoriatic arthritis was more frequent in the OTO group (5.1% versus 16.7% respectively; <em>P</em> = 0.03) and in the overweight and obese subgroups (5.1% versus 14.3% and 20.0%, respectively; <em>P</em> = 0.08). Analysis of PASI scores after 3 months of treatment suggested that biologic therapy efficacy was higher for the OTO group than the normal weight group. Drug continuation rates tended to be lower for the OTO group, particularly for adalimumab (<em>P</em> = 0.0002).</div></div><div><h3>Discussion</h3><div>OTO status was associated with a higher frequency of psoriatic arthritis in children with psoriasis. Except for lower rates of adalimumab continuation, overall biologic therapy efficacy was similar in the normal and OTO groups. Studies involving larger cohorts are needed to confirm these findings.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103376"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse molluscum contagiosum associated with GATA2 deficiency","authors":"C. Bourseau-Quetier,&nbsp;M.-S. Doutre","doi":"10.1016/j.annder.2025.103378","DOIUrl":"10.1016/j.annder.2025.103378","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103378"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143892053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy","authors":"A. Duplaine ,&nbsp;J. Tannous ,&nbsp;J. Seneschal ,&nbsp;K. Ezzedine ,&nbsp;T. Passeron ,&nbsp;N. Dupin ,&nbsp;G. Quereux ,&nbsp;M. Beylot-Barry ,&nbsp;O. Chosidow ,&nbsp;B. Guillot ,&nbsp;for the Centre of Evidence of the French Society of Dermatology","doi":"10.1016/j.annder.2025.103352","DOIUrl":"10.1016/j.annder.2025.103352","url":null,"abstract":"<div><h3>Background</h3><div>Vitiligo, a prevalent depigmenting condition, affects both adults and children, significantly impacting their quality of life. The standard treatment approach involves the application of topical corticosteroids in conjunction with narrow-band ultraviolet B (UVB) phototherapy. A novel topical treatment, ruxolitinib (a Janus kinase inhibitor), has recently received approval. Notwithstanding the absence of marketing authorization for this particular indication in France, numerous practitioners have adopted the use of tacrolimus ointment 0.1% for the treatment of vitiligo, frequently in conjunction with phototherapy. The objective of this study is to present the benefit/risk ratio of tacrolimus in the treatment of vitiligo.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted by the Centre of Evidence (CDP) of the French Society of Dermatology (SFD) to ascertain the efficacy and safety of topical calcineurin inhibitors (TCIs) in vitiligo. The search strategy encompassed meta-analyses (MAs) and prospective multicentric cohort studies.</div></div><div><h3>Results</h3><div>Literature data – in particular three meta-analyses and one randomised controlled trial – confirm the superiority of tacrolimus versus placebo and its non-inferiority versus super-potent topical corticosteroids. In a subgroup analysis, tacrolimus suggests superior efficacy in children and in facial vitiligo. The combined use of tacrolimus and phototherapy exhibited synergistic efficacy.</div></div><div><h3>Conclusion</h3><div>Notwithstanding the market access of topical ruxolitinib, tacrolimus remains a viable treatment option for vitiligo, as substantiated by extant efficacy and safety in the literature. A recent decision of the French National Agency for the Safety of Medicines and Health Products (ANSM) authorized the compassionate prescription of tacrolimus and its reimbursement for patients.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103352"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asynchronous radiation recall dermatitis on two different irradiated areas","authors":"I. Berkaoui,&nbsp;N. Litrowski,&nbsp;C. Boulard","doi":"10.1016/j.annder.2025.103372","DOIUrl":"10.1016/j.annder.2025.103372","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103372"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-interleukin-23-associated alopecia areata in patients with psoriasis: two cases and a literature review","authors":"Y. Hameg,&nbsp;S. Vildy,&nbsp;E. Mahé,&nbsp;the Groupe de Recherche sur le Psoriasis GRPso of the Société Française de Dermatologie","doi":"10.1016/j.annder.2025.103374","DOIUrl":"10.1016/j.annder.2025.103374","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103374"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}